Jiangsu Jibeier Pharmaceutical Co Ltd (688566) - Total Assets
Based on the latest financial reports, Jiangsu Jibeier Pharmaceutical Co Ltd (688566) holds total assets worth CN¥2.64 Billion CNY (≈ $386.27 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Jiangsu Jibeier Pharmaceutical Co Ltd's book value for net asset value and shareholders' equity analysis.
Jiangsu Jibeier Pharmaceutical Co Ltd - Total Assets Trend (2016–2024)
This chart illustrates how Jiangsu Jibeier Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data.
Jiangsu Jibeier Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Jiangsu Jibeier Pharmaceutical Co Ltd's total assets of CN¥2.64 Billion consist of 51.6% current assets and 48.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 33.5% |
| Accounts Receivable | CN¥366.01 Million | 14.5% |
| Inventory | CN¥30.70 Million | 1.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥88.45 Million | 3.5% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Jiangsu Jibeier Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Jiangsu Jibeier Pharmaceutical Co Ltd worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangsu Jibeier Pharmaceutical Co Ltd's current assets represent 51.6% of total assets in 2024, a decrease from 58.5% in 2016.
- Cash Position: Cash and equivalents constituted 33.5% of total assets in 2024, up from 27.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, a decrease from 11.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 14.5% of total assets.
Jiangsu Jibeier Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangsu Jibeier Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Zhejiang Huahai Pharmaceutical Co Ltd
SHG:600521
|
China | CN¥21.15 Billion |
|
Emcure Pharmaceuticals Ltd
NSE:EMCURE
|
India | Rs93.93 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr67.43 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.02 Billion |
Jiangsu Jibeier Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.37 | 9.28 | 17.97 |
| Quick Ratio | 7.17 | 9.03 | 17.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.14 Billion | CN¥1.18 Billion | CN¥1.43 Billion |
Jiangsu Jibeier Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangsu Jibeier Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.74 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | 14.4% |
| Total Assets | CN¥2.53 Billion |
| Market Capitalization | $821.50 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangsu Jibeier Pharmaceutical Co Ltd's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Jiangsu Jibeier Pharmaceutical Co Ltd's assets grew by 14.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Jiangsu Jibeier Pharmaceutical Co Ltd (2016–2024)
The table below shows the annual total assets of Jiangsu Jibeier Pharmaceutical Co Ltd from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.53 Billion ≈ $369.86 Million |
+14.39% |
| 2023-12-31 | CN¥2.21 Billion ≈ $323.34 Million |
+12.48% |
| 2022-12-31 | CN¥1.96 Billion ≈ $287.48 Million |
+8.02% |
| 2021-12-31 | CN¥1.82 Billion ≈ $266.13 Million |
+4.09% |
| 2020-12-31 | CN¥1.75 Billion ≈ $255.68 Million |
+193.35% |
| 2019-12-31 | CN¥595.62 Million ≈ $87.16 Million |
+24.61% |
| 2018-12-31 | CN¥477.99 Million ≈ $69.95 Million |
-9.42% |
| 2017-12-31 | CN¥527.68 Million ≈ $77.22 Million |
+9.44% |
| 2016-12-31 | CN¥482.14 Million ≈ $70.55 Million |
-- |
About Jiangsu Jibeier Pharmaceutical Co Ltd
Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company's products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing… Read more